Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Insights, Forecast to 2034
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
Global Glucagon-like peptide 1 (GLP-1)-based Therapies market is expected to reach to US$ 5710 million in 2024, with a positive growth of %, compared with US$ 5387 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Glucagon-like peptide 1 (GLP-1)-based Therapies industry is evaluated to reach US$ 7350.9 million in 2029. The CAGR will be 4.3% during 2024 to 2029.
The Glucagon-like peptide 1 (GLP-1) market is driven by the increasing prevalence of diabetes and the growing demand for effective and innovative diabetes treatments. GLP-1 is a hormone that plays a crucial role in regulating blood sugar levels and is used in the treatment of type 2 diabetes. The rise in the number of diabetic patients and the need for better glycemic control contribute to market growth as GLP-1-based therapies offer significant benefits, including glucose-lowering effects and weight management. Moreover, advancements in GLP-1 analog formulations, such as long-acting and once-weekly options, have improved patient compliance and treatment outcomes. However, the market also faces challenges, including the cost of GLP-1 treatments and the need for further research to optimize dosing and combination therapies. Additionally, addressing the barriers to GLP-1 adoption, such as injection-related fears, can pose obstacles for broader market penetration. To succeed, companies must focus on research and development to offer innovative and cost-effective GLP-1 therapies, collaborate with healthcare providers to optimize treatment regimens, and address the challenges to meet the increasing demand for effective and well-tolerated diabetes treatments based on GLP-1.
Report Covers
This report presents an overview of global Glucagon-like peptide 1 (GLP-1)-based Therapies market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Glucagon-like peptide 1 (GLP-1)-based Therapies market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Abbott Laboratories
Segment by Type
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Hospital
Pharmacy
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Glucagon-like peptide 1 (GLP-1)-based Therapies plant distribution, commercial date of Glucagon-like peptide 1 (GLP-1)-based Therapies, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Glucagon-like peptide 1 (GLP-1)-based Therapies introduction, etc. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Glucagon-like peptide 1 (GLP-1)-based Therapies
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global Glucagon-like peptide 1 (GLP-1)-based Therapies market is expected to reach to US$ 5710 million in 2024, with a positive growth of %, compared with US$ 5387 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Glucagon-like peptide 1 (GLP-1)-based Therapies industry is evaluated to reach US$ 7350.9 million in 2029. The CAGR will be 4.3% during 2024 to 2029.
The Glucagon-like peptide 1 (GLP-1) market is driven by the increasing prevalence of diabetes and the growing demand for effective and innovative diabetes treatments. GLP-1 is a hormone that plays a crucial role in regulating blood sugar levels and is used in the treatment of type 2 diabetes. The rise in the number of diabetic patients and the need for better glycemic control contribute to market growth as GLP-1-based therapies offer significant benefits, including glucose-lowering effects and weight management. Moreover, advancements in GLP-1 analog formulations, such as long-acting and once-weekly options, have improved patient compliance and treatment outcomes. However, the market also faces challenges, including the cost of GLP-1 treatments and the need for further research to optimize dosing and combination therapies. Additionally, addressing the barriers to GLP-1 adoption, such as injection-related fears, can pose obstacles for broader market penetration. To succeed, companies must focus on research and development to offer innovative and cost-effective GLP-1 therapies, collaborate with healthcare providers to optimize treatment regimens, and address the challenges to meet the increasing demand for effective and well-tolerated diabetes treatments based on GLP-1.
Report Covers
This report presents an overview of global Glucagon-like peptide 1 (GLP-1)-based Therapies market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Glucagon-like peptide 1 (GLP-1)-based Therapies market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Abbott Laboratories
Segment by Type
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Segment by Application
Hospital
Pharmacy
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Glucagon-like peptide 1 (GLP-1)-based Therapies plant distribution, commercial date of Glucagon-like peptide 1 (GLP-1)-based Therapies, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Glucagon-like peptide 1 (GLP-1)-based Therapies introduction, etc. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Glucagon-like peptide 1 (GLP-1)-based Therapies
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices